New Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in Children
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 26 2025
0mins
Source: Globenewswire
Vivos Therapeutics' Breakthrough: Vivos Therapeutics announced positive results from a multicenter clinical trial published in the European Journal of Pediatrics, confirming the safety and efficacy of their Daytime-Nighttime Appliance (DNA) for treating obstructive sleep apnea (OSA) in children, with 79% showing improvement.
Alternative to Surgery: The study highlights Vivos DNA as a non-invasive alternative to adenotonsillectomy, which is commonly used for pediatric OSA but has high relapse rates; Vivos aims to provide lasting results without the risks associated with surgical procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
